g.tanaka
TL3 Regular · Nagoya, JP
Materials scientist. Adsorption to surfaces, container closure, and why concentration matters for losses.
Joined 22 October 2024 · last posted 3d · groups: analytical-chemists
144 posts, newest first. Showing up to 150.
-
[2026 update] Detection wavelength and why 214 nm and 280 nm disagree Replied, post #69 · Analytics › HPLC & UHPLC · 25 Jul 2026 · 4 likes If two laboratories disagree by more than two or three percentage points, work through method, integration, sample handling, whether it was the same lot and the same…
-
Revisiting: The best-written scientific paper you have read Replied, post #115 · Lounge › Off topic · 25 Jul 2026 · 10 likes Off-topic but genuinely curious: how many people here came in through the analytics side rather than the practical side? The two groups seem to read completely…
-
Coming back to: Preparing for an appointment: one page, three questions Replied, post #10 · Clinical › Prescriber conversations · 17 Jul 2026 · 0 likes Prescription logistics: confirm whether it will be filled locally, requires mail order, or will be prescribed off-label and needs a compounding pharmacy. Different…
-
Why the Start Here categories exist, and what they are not for Replied, post #8 · Start Here › Welcome · 17 Jul 2026 · 0 likes Marked solutions are the site's way of saying that someone asked a good question and someone else gave an answer that actually worked. It is not a competition and it…
-
What is genuinely unknown about long-term amylin agonism Replied, post #44 · Compounds › Cagrilintide & amylin analogues · 16 Jul 2026 · 0 likes This settles it for me, at least until somebody posts a reason it should not.
-
Coming back to: Time to steady state after a dose increase Replied, post #102 · Pharmacology › Pharmacokinetics · 16 Jul 2026 · 0 likes Between-person variability in exposure is substantial and is the reason two people on the same dose can have quite different plasma concentrations. That is inherent…
-
Follow-up: The most useful thing you learned here that was not the answer you came for Replied, post #26 · Lounge › Off topic · 15 Jul 2026 · 19 likes Since the Lounge tolerates a digression: the thing I find most interesting about this community is how much of the useful material is negative. Half the value is…
-
What a certificate commits its issuer to — the long version Replied, post #23 · Analytics › COA interpretation · 13 Jul 2026 · 2 likes Confirming post #20 from a second method, which matters more than confirming it from a second person. Asking for the batch record rather than the certificate is a…
-
Reading a rodent study on a secretagogue without over-extrapolating — the long version Replied, post #36 · Compounds › Secretagogues & GH axis · 12 Jul 2026 · 1 like On post #32 — agreed on the reasoning, with one qualification. I would rather this thread reach "we do not know" about Reading a rodent study than reach a confident…
-
Endotoxin and why it is a separate question from purity — what changed since Replied, post #69 · Analytics › Impurities & related substances · 7 Jul 2026 · 17 likes Truncation products: fragments from incomplete synthesis or from degradation. They elute quite differently from the intact peptide because they are much smaller and…
-
SURPASS-2 and the comparator dose question that will not go away — what changed since Replied, post #4 · Compounds › Tirzepatide · 4 Jul 2026 · 24 likes Quietly grateful for the plain phrasing. Not every thread gets that.
-
Adolescents: a distinct evidence base Replied, post #3 · Clinical › Special populations · 3 Jul 2026 · 0 likes Adolescents: a distinct evidence base exists. The compounds are not approved for routine adolescent obesity but are being studied. Adolescent physiology and psychology…
-
Reading a home test result without over-claiming Replied, post #103 · Analytics › Home & field testing · 2 Jul 2026 · 18 likes A test that gives a yes or no on the presence of peptide bonds is answering a genuinely useful question if that is the question you had. It is not a purity assay and…
-
Muscle cramps: the ordinary causes before the exotic ones — a second dataset Replied, post #22 · Practice › Side effects · 30 Jun 2026 · 0 likes Everything in post #21 holds. The case it does not cover is the one I have. An update on my earlier Muscle cramps post: the pattern held for another six weeks and then…
-
Private prescribing in the UK: what is actually involved Replied, post #44 · Regional › UK & Ireland · 21 Jun 2026 · 23 likes This is the answer, and the reason it is the answer is the more useful part.
-
A critique that turned out to be unfair, retracted by its author Replied, post #16 · Evidence › Study critique · 21 Jun 2026 · 1 like Understood, and I withdraw the assumption I opened with.
-
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Replied, post #70 · Compounds › Semaglutide · 19 Jun 2026 · 11 likes Small methodological point on semaglutide and gastric emptying: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to…
-
Coming back to: Swirling versus inverting versus leaving it alone Replied, post #22 · Practice › Reconstitution · 19 Jun 2026 · 3 likes Do not shake. Swirl, or leave it. Vigorous agitation introduces air and shear, and neither helps a peptide go into solution any faster than patience does.
-
Primary endpoint hierarchies and why order matters — one year on Replied, post #19 · Evidence › Trials · 18 Jun 2026 · 6 likes On Primary endpoint hierarchies the community has more anecdote than the confidence in this thread implies, and I include my own contribution in that.
-
An 18-month record including the parts that went badly Replied, post #44 · Outcomes › Progress reports · 18 Jun 2026 · 30 likes Post #41 is right about the mechanism and I think understates the practical bit. I disagree with the framing of 18-month record above, and I think it is a substantive…
-
An appeal that succeeded, with the letter structure — the long version Replied, post #87 · Access › Insurance & coverage · 12 Jun 2026 · 0 likes Formulary status: the list of covered medications and the tier (how much you pay) they are on. Checking the current formulary before going to a clinic appointment saves…
-
Peak-to-trough ratio at steady state for a weekly agent — the long version Replied, post #23 · Pharmacology › Pharmacokinetics · 12 Jun 2026 · 5 likes Worth separating two things that post #21 runs together. Reading this Peak-to-trough ratio thread as someone who came in with a fixed view: the third and seventh…
-
Follow-up: A parcel that arrived warm: a decision process, not a verdict Replied, post #60 · Practice › Storage & stability · 6 Jun 2026 · 9 likes Narrowing post #57, because the general version has more than one answer. Visible particulate is a strong signal in the other direction: it is a reason to stop and ask…
-
Review: a draft on reconstitution arithmetic, with objections — one year on Replied, post #22 · Documentation › Doc review · 4 Jun 2026 · 0 likes Adding a reference point for draft on reconstitution arithmetic. Mine is a single case, collected without controls, and I am posting the method alongside it so it can…
-
Comparing prices across jurisdictions without misleading yourself Replied, post #31 · Access › Pricing · 2 Jun 2026 · 0 likes Narrowing post #30, because the general version has more than one answer. The site carries no prices, no payment routes and no supplier links beyond the documented…
-
Primary endpoint hierarchies and why order matters — one year on Replied, post #5 · Evidence › Trials · 1 Jun 2026 · 24 likes Taking post #2 at face value and following it one step further. Open-label design: unblinded trials admit expectation effects. For weight-loss trials where one arm…
-
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #78 · Evidence › Journal club · 31 May 2026 · 0 likes On post #74 — agreed on the reasoning, with one qualification. Distinguishing three things in the orforglipron phase 2 discussion that keep getting used…
-
[2026 update] A vial that will not fully dissolve: what to check and in what order Replied, post #79 · Practice › Reconstitution · 29 May 2026 · 6 likes Post #75 put the caveat in the right place and I want to underline it. Concentration is total mass divided by total volume, and everything else follows from that. Ten…
-
Tracking intake honestly when appetite is absent Replied, post #41 · Nutrition & Training › Protein & intake · 29 May 2026 · 2 likes Thank you for taking the time. That was more work than a reply usually is.
-
Coming back to: Time to steady state after a dose increase Replied, post #63 · Pharmacology › Pharmacokinetics · 28 May 2026 · 22 likes Where I part company with post #62, and it is a narrow parting. Half-life determines how quickly concentration approaches steady state and does not determine what the…
-
Molecular mass of semaglutide and why the figure differs between sources Replied, post #64 · Compounds › Semaglutide · 26 May 2026 · 21 likes Building on post #63 rather than restating it. Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not…
-
Second pass at: Which categories are strict and which are relaxed, honestly Replied, post #62 · Start Here › Welcome · 23 May 2026 · 0 likes The FAQ link in the sidebar is maintained and worth ten hours of forum browsing. It is not comprehensive but it is well indexed for the questions that come up most.
-
An appeal that succeeded, with the letter structure — the long version Started this topic · Access › Insurance & coverage · 20 May 2026 · 33 likes An appeal that succeeded, with the letter structure — the long version — setting out what I have, and where I think it stops being reliable. A narrow question about…
-
Review: a draft on reconstitution arithmetic, with objections — one year on Replied, post #13 · Documentation › Doc review · 16 May 2026 · 3 likes Reviewing your own nomination is fine and is not sufficient. Somebody else has to read it for the process to mean anything.
-
Hair shedding at month three: mechanism and time course — the long version Replied, post #11 · Practice › Side effects · 14 May 2026 · 17 likes Dehydration is the mechanism behind more of the secondary complaints here than people expect. Reduced intake plus vomiting plus a warm week is a straightforward path to…
-
Coming back to: Specificity, linearity, accuracy, precision, range, robustness — with… Replied, post #18 · Analytics › Method validation · 11 May 2026 · 3 likes Precision and repeatability: within-run and between-run variability of the method. Acceptance criterion is typically a relative standard deviation of ≤2% for area…
-
[2026 update] Correlation in a self-tracked dataset: what it can support Started this topic · Research Methods › Statistics · 30 Apr 2026 · 50 likes Posting this under the heading it deserves: Correlation in a self-tracked dataset: what it can support Everything below is what sits behind that. Posting a small…
-
Endotoxin and why it is a separate question from purity — what changed since Replied, post #8 · Analytics › Impurities & related substances · 30 Apr 2026 · 18 likes Noted, and thank you for writing it out rather than summarising it.
-
Follow-up: Search filters: what is missing Replied, post #87 · Meta › Site feedback · 27 Apr 2026 · 0 likes Seconding that. I would put solved-only in front of the sort control rather than behind it. A weak preference rather than a position.
-
Anaesthesia and elective surgery: the aspiration question Replied, post #90 · Practice › Interactions · 17 Apr 2026 · 0 likes Anticoagulant questions come up regularly and are the clearest case for professional advice rather than discussion, because the consequence of being wrong is not…
-
Second pass at: Fasting versus non-fasting and which tests care Replied, post #24 · Clinical › Bloodwork · 7 Apr 2026 · 30 likes I had read the opposite somewhere and cannot now find where, which tells me something.
-
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #27 · Evidence › Journal club · 30 Mar 2026 · 3 likes Coming back to post #25, because the follow-up matters more than the original answer. Recording who prepared each section makes the summary attributable, which matters…
-
Choosing which test to pay for, given a fixed budget Replied, post #40 · Sourcing › Independent verification · 26 Mar 2026 · 1 like Building on post #37 rather than restating it. Repeat testing: if you want to verify the same lot a second time, testing with a different service strengthens the…
-
Stepping down deliberately, and how to do it without losing progress Replied, post #74 · Practice › Dosing & titration · 15 Mar 2026 · 4 likes Noted, and I have changed what I was going to do on the strength of it.
-
Charge states for a 4 kDa peptide, worked through — the long version Replied, post #2 · Analytics › Mass spectrometry · 12 Mar 2026 · 0 likes Electrospray ionisation produces multiply charged ions. For a 4 kDa peptide you expect mostly 2+, 3+, and 4+ charge states. Reading an electrospray spectrum means…
-
Reading a preclinical wound-healing model and its relevance to a human tendon — a second… Replied, post #43 · Compounds › Repair & healing peptides · 12 Mar 2026 · 0 likes The number people quote for Reading a preclinical wound-healing model is a central estimate presented without its interval, and the interval is wide enough that the…
-
Pharmacy supply in the UK and the questions you will be asked Replied, post #73 · Regional › UK & Ireland · 12 Mar 2026 · 18 likes Pharmacy practice varies between pharmacies and is not deducible from the regulatory position. Two people can honestly report opposite experiences. The evidence for…
-
Pregnancy and pregnancy planning: contraindication and washout Replied, post #67 · Clinical › Special populations · 9 Mar 2026 · 10 likes Medullary thyroid carcinoma history: an absolute contraindication because of the preclinical findings in rodent toxicology. The history (personal or family, especially…
-
The lowest dose that does anything: is that a real question? Replied, post #90 · Practice › Dosing & titration · 7 Mar 2026 · 0 likes On post #88 — agreed on the reasoning, with one qualification. The arithmetic of an intermediate dose: if the label says 1.0 mg and 2.0 mg, a dose strictly between them…
-
Contributing data without breaching anyone's privacy Replied, post #6 · Data & Tools › Datasets · 2 Mar 2026 · 2 likes Sensible. I would want the same detail before I acted on it either.
-
Revisiting: Maintainer handover: how it works Replied, post #14 · Meta › Wiki maintenance · 24 Feb 2026 · 25 likes The most useful thing anyone has posted about Maintainer handover in this category was a table of what had been measured and by whom. That is what I would want again.
-
Second pass at: Adsorptive losses at low concentration, and why dilute solutions are… Replied, post #48 · Practice › Storage & stability · 24 Feb 2026 · 0 likes No notes. Posting so the count is not one.
-
Measurement error in a self-reported exposure Replied, post #38 · Evidence › Study critique · 23 Feb 2026 · 9 likes Generalisability and validity are separate axes. A trial can be internally impeccable and still tell you nothing about the person asking.
-
Specification in the result column: why that is a meaningful error Replied, post #127 · Analytics › COA interpretation · 23 Feb 2026 · 3 likes A certificate is a statement by its issuer that a defined test was performed on a defined lot and produced a defined result. That is all it is, and it is not nothing.…
-
Storing lyophilised material long term: what governs the shelf life Replied, post #67 · Practice › Storage & stability · 16 Feb 2026 · 11 likes The thing about storing lyophilised material long term that took me longest to accept is that a plausible mechanism is not evidence of an effect. It is a reason to…
-
Storing lyophilised material long term: what governs the shelf life Replied, post #56 · Practice › Storage & stability · 8 Feb 2026 · 26 likes On storing lyophilised material long term, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of…
-
Non-inferiority margins: how they are chosen and how they are abused — a second dataset Replied, post #24 · Evidence › Trials · 7 Feb 2026 · 5 likes Confirming post #23 from a second method, which matters more than confirming it from a second person. Pre-specification is the property that makes a primary endpoint…
-
Coming back to: Reading a supplier's product description as a marketing document Replied, post #14 · Compounds › Other compounds · 4 Feb 2026 · 1 like Why catalogue breadth is not evidence of anything: a supplier listing 500 compounds does not make the 450 untested ones likely to work. It makes them untested compounds…
-
Second pass at: Pregnancy and pregnancy planning: contraindication and washout Replied, post #120 · Clinical › Special populations · 27 Jan 2026 · 3 likes Confirming post #118 from a second method, which matters more than confirming it from a second person. Pregnancy and pregnancy planning has a well-known answer and a…
-
Reconstitution volumes that produce round numbers, tabulated Replied, post #28 · Practice › Reconstitution · 18 Jan 2026 · 7 likes Preservative effectiveness is tested against a defined microbial challenge under defined conditions. It is not a licence to treat an entered vial as sterile…
-
Foaming during reconstitution and whether it matters — the long version Replied, post #6 · Practice › Reconstitution · 10 Jan 2026 · 13 likes I disagree with the framing of Foaming during reconstitution above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so…
-
Temperature loggers worth the money — the long version Replied, post #103 · Devices › Cold chain · 30 Dec 2025 · 29 likes I read post #99 twice before replying, because I had assumed the opposite. Customs holds are the most common cause of an unexpectedly long transit, and they are also…
-
Vomiting: when it is expected and when it is a reason to stop Replied, post #106 · Practice › Side effects · 30 Dec 2025 · 12 likes Post #105 is right about the mechanism and I think understates the practical bit. The relationship between symptom burden and outcome is not what people assume. Feeling…
-
Temperature indicator cards: worth asking for? Started this topic · Sourcing › Logistics · 28 Dec 2025 · 5 likes Asking directly, because I could not find a straight answer: Temperature indicator cards: worth asking for? Two things I would like separated before anyone answers on…
-
Reconstitution volumes that produce round numbers, tabulated Replied, post #15 · Practice › Reconstitution · 27 Dec 2025 · 33 likes I will take the caveat as seriously as the claim, which is the point of putting it there.
-
Revisiting: Sample handling between despatch and injection Replied, post #3 · Analytics › Method validation · 25 Dec 2025 · 3 likes The arithmetic in the opening post is right; the assumption feeding it is the part to check. The most useful single question about a method: what would it fail to…
-
The decimal-point error, and the habit that catches it Replied, post #9 · Practice › Reconstitution · 13 Dec 2025 · 23 likes Write the reconstitution date and the concentration on the vial. Not on a note, on the vial. Every account here of a dosing error involving the wrong concentration…
-
[2026 update] How much of the diluent volume the powder itself displaces Replied, post #58 · Practice › Reconstitution · 25 Nov 2025 · 0 likes Answering the question post #54 raises rather than the one it answers. Concentration is total mass divided by total volume, and everything else follows from that. Ten…
-
Documentation that materially improves an appeal's chances Replied, post #76 · Access › Insurance & coverage · 24 Nov 2025 · 0 likes The strongest argument against my own position on documentation, stated as well as I can state it, since nobody else has yet.
-
[2026 update] Why mass spectrometry cannot tell you about an epimer Started this topic · Analytics › Mass spectrometry · 22 Nov 2025 · 9 likes Why mass spectrometry cannot tell you about an epimer — that is the question, and I have not found it answered plainly anywhere I have looked. Working through the…
-
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ — a second dataset Replied, post #8 · Sourcing › Independent verification · 15 Nov 2025 · 24 likes A record with four results over sixteen months is a thin record rather than a bad one, and the honest description says which. A partial answer, offered because a…
-
How the vendor documentation pages are maintained, and by whom — what changed since Replied, post #91 · Sourcing › Vendor reports · 14 Nov 2025 · 20 likes Two things can be true about vendor documentation pages at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the argument…
-
Older adults, sarcopenia risk, and the trade-off nobody quantifies — the long version Replied, post #46 · Clinical › Special populations · 5 Nov 2025 · 4 likes I would rather this thread reach "we do not know" about Older adults than reach a confident answer that nobody can support when asked.
-
Persistent vomiting and the threshold for seeking help Replied, post #63 · Safety › Adverse events · 5 Nov 2025 · 7 likes Reporting to regulatory agencies: if you have had a serious event, reporting it to the regulatory agency in your country can help with signal detection across the…
-
Comparing my trajectory with the trial curves, carefully Replied, post #68 · Outcomes › Progress reports · 29 Oct 2025 · 0 likes Rate of change matters more than the absolute number for most of the questions people ask about their own series.
-
Adolescents: a distinct evidence base — one year on Replied, post #26 · Clinical › Special populations · 19 Oct 2025 · 7 likes The absence of a reported signal in a population that was barely enrolled is not evidence about that population. The rule of thumb is fine; the edge cases are where it…
-
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Replied, post #2 · Compounds › Tirzepatide · 18 Oct 2025 · 8 likes The opening post and I disagree about the size of the effect, not about the direction. What I can speak to on SURMOUNT-4 is narrow, so I will keep it narrow rather than…
-
Insomnia at a dose step: reported experiences Replied, post #17 · Wellbeing › Sleep · 14 Oct 2025 · 5 likes The practical version of insomnia is three sentences long. The rigorous version is three pages and reaches the same conclusion with the conditions attached.
-
The most useful thing you learned here that was not the answer you came for — a second… Replied, post #53 · Lounge › Off topic · 23 Sep 2025 · 17 likes Since the Lounge tolerates a digression: the thing I find most interesting about this community is how much of the useful material is negative. Half the value is…
-
What this community means by "a source", in practical terms Replied, post #118 · Start Here › Welcome · 18 Sep 2025 · 6 likes Helpful, and short, which on this subject is harder than long.
-
Documenting an adverse event properly Replied, post #11 · Safety › Adverse events · 15 Sep 2025 · 0 likes Pancreatitis is a genuine serious adverse event to know: severe epigastric pain, back pain, elevated lipase (≥3× upper limit of normal). If this constellation appears,…
-
Why "any advice?" is the least effective ending for a post — the long version Replied, post #52 · Start Here › How to Ask · 11 Sep 2025 · 0 likes Asking a follow-up: new topic or reply in the old one? If the answer depends on the previous post, reply. If it is a question that makes sense without the previous…
-
Needle changes between doses on a reusable pen Replied, post #33 · Devices › Pens & autoinjectors · 5 Sep 2025 · 11 likes Storage after first use: most pens can be stored at room temperature after first use, even if unrefrigerated, for a limited time (often 28 days). Check your specific…
-
Are there stupid questions here? A staff answer, at length Replied, post #148 · Start Here › Welcome · 3 Sep 2025 · 12 likes The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
-
Immortal time bias in a claims-database study Replied, post #35 · Evidence › Study critique · 31 Aug 2025 · 0 likes Publication bias: a single published positive trial is weaker evidence than multiple published trials with consistent results. Asking whether there are unpublished…
-
Are there stupid questions here? A staff answer, at length Replied, post #117 · Start Here › Welcome · 26 Aug 2025 · 7 likes The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
-
Fatigue in the first month: how much is the drug and how much is intake — what changed… Replied, post #25 · Practice › Side effects · 9 Aug 2025 · 33 likes Delayed gastric emptying: the mechanism behind much of the gastrointestinal side-effect profile. At extreme magnitudes, severe gastroparesis is a rare but serious…
-
High-resolution MS on aggregates and what it can see Replied, post #36 · Analytics › Mass spectrometry · 3 Aug 2025 · 6 likes The arithmetic in post #35 is right; the assumption feeding it is the part to check. Mass accuracy is expressed in parts per million. It is the difference between…
-
Are there stupid questions here? A staff answer, at length Replied, post #30 · Start Here › Welcome · 1 Aug 2025 · 22 likes Adding thanks rather than a view. I do not have a view worth the space.
-
A ten-fold dose error caught before injection — one year on Replied, post #16 · Devices › Syringes & needles · 1 Aug 2025 · 17 likes Drawing air into the vial before withdrawing liquid equalises the pressure and makes the draw easier. It is not required and it is why some people find a full vial…
-
Detection wavelength and why 214 nm and 280 nm disagree Replied, post #26 · Analytics › HPLC & UHPLC · 31 Jul 2025 · 15 likes I had written a reply contradicting post #23 and deleted it. Here is what survived. Peak purity: a diode-array detector records a spectrum at every time point. If a…
-
How to research a compound with no human data without deceiving yourself Replied, post #7 · Compounds › Other compounds · 29 Jul 2025 · 1 like The arithmetic in post #6 is right; the assumption feeding it is the part to check. PT-141 was developed from the same family with a different receptor profile, and it…
-
Airline travel with a temperature-sensitive injectable — what changed since Replied, post #56 · Devices › Cold chain · 28 Jul 2025 · 30 likes Post #52 and I disagree about the size of the effect, not about the direction. I have no financial interest in anything named in this thread and I want to say so before…
-
Coming back to: Why quantitation is the hard part, not detection Replied, post #43 · Analytics › Home & field testing · 26 Jul 2025 · 0 likes Confirming post #40 from a second method, which matters more than confirming it from a second person. Adding what did not work for me on quantitation, since the…
-
The CagriSema phase 2 paper and what a fixed combination buys Replied, post #69 · Compounds › Cagrilintide & amylin analogues · 15 Jul 2025 · 28 likes Adding the measurement that post #66 says would settle it. Cagrilintide alone is discussed less than in combination because the published data is almost entirely from…
-
Reading a supplier's product description as a marketing document Replied, post #42 · Compounds › Other compounds · 8 Jul 2025 · 12 likes Where a compound has a legitimate pharmaceutical form somewhere in the world, the labelling for that form is usually the single most useful document available and is…
-
Follow-up: Tracking intake honestly when appetite is absent Replied, post #83 · Nutrition & Training › Protein & intake · 13 Jun 2025 · 0 likes Where I part company with post #79, and it is a narrow parting. Liquid sources are tolerated better than solid ones by many people here, and that is a practical…
-
Why fasting instructions for oral semaglutide are not optional advice — does this still… Replied, post #46 · Compounds › Oral incretins · 12 Jun 2025 · 22 likes Coming back to post #44, because the follow-up matters more than the original answer. The SOUL trial: cardiovascular outcomes trial for oral semaglutide in people with…
-
The CagriSema phase 2 paper and what a fixed combination buys — the long version Replied, post #48 · Compounds › Cagrilintide & amylin analogues · 9 Jun 2025 · 12 likes The CagriSema phase 2 paper: a fixed combination of the two components in one weekly injection. The trade-off of a fixed combination is that you cannot titrate the…
-
Why we hide unevidenced fraud accusations and log the hiding Replied, post #107 · Sourcing › Red flags · 6 Jun 2025 · 24 likes Where somebody posts a concern, ask what would resolve it before arguing about it. Half of these threads end with a document nobody had asked for. I checked the source…
-
DXA precision and the least significant change for lean mass — the long version Replied, post #100 · Outcomes › Body composition · 26 May 2025 · 1 like Post #99 is the version of this I will quote in future. One addition. DXA precision looks different depending on whether you are reading the primary literature or the…
-
Revisiting: Why a compound being unapproved is not the same as being illegal to possess Replied, post #9 · Sourcing › Regulatory · 22 May 2025 · 12 likes Narrowing post #6, because the general version has more than one answer. Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one…
-
Second pass at: Retatrutide mass and identity: what a report should show Replied, post #45 · Compounds › Retatrutide · 17 May 2025 · 2 likes On post #41 — agreed on the reasoning, with one qualification. Retatrutide is investigational. Material obtained outside a clinical trial is research-use-only by…
-
When to stop reading forums, including this one — the long version Replied, post #21 · Wellbeing › Mental health · 17 May 2025 · 32 likes If you are in crisis, contact a local emergency or crisis service rather than posting. A volunteer forum cannot help and waiting costs time.
-
A well-designed study with a badly written abstract Replied, post #46 · Evidence › Study critique · 27 Apr 2025 · 0 likes Attrition is the failure mode most likely to invalidate a result and the least likely to be discussed. Differential attrition between arms is the specific thing to look…
-
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how… Replied, post #45 · Compounds › Tirzepatide · 26 Apr 2025 · 0 likes On purity: the trailing-edge features people report on tirzepatide chromatograms are frequently deamidation products, which elute close to the main peak and are easy to…
-
Second pass at: A history of disordered eating: proceeding carefully Replied, post #37 · Wellbeing › Mental health · 20 Apr 2025 · 12 likes Disordered eating history: a history of anorexia, bulimia, or other eating disorders changes the risk-benefit calculation. Appetite suppression might trigger relapse.…
-
A page that has drifted out of date and needs a maintainer Replied, post #89 · Documentation › Wiki requests · 13 Apr 2025 · 18 likes A request that says what the page should not cover is unusually helpful, because scope creep is what kills these.
-
A well-designed study with a badly written abstract Replied, post #7 · Evidence › Study critique · 2 Apr 2025 · 2 likes Narrowing post #4, because the general version has more than one answer. The number people quote for well-designed study is a central estimate presented without its…
-
BPC-157: what the rodent literature actually shows, and what it does not — a second… Replied, post #24 · Compounds › Repair & healing peptides · 17 Mar 2025 · 6 likes I had written a reply contradicting post #22 and deleted it. Here is what survived. Publication patterns in the BPC-157 literature: a large proportion of the evidence…
-
Charge states for a 4 kDa peptide, worked through Replied, post #82 · Analytics › Mass spectrometry · 12 Mar 2025 · 0 likes Everything in post #80 holds. The case it does not cover is the one I have. Distinguishing three things in the charge states discussion that keep getting used…
-
Charge states for a 4 kDa peptide, worked through Replied, post #61 · Analytics › Mass spectrometry · 9 Mar 2025 · 1 like This follows post #60 rather than contradicting it. Charge states sits at the boundary between what this community can usefully discuss and what it cannot, and I think…
-
Consistent declarations and why they matter more than clever ones Replied, post #142 · Sourcing › Logistics · 7 Mar 2025 · 11 likes Border outcomes are not predictable at the level of an individual parcel. What is predictable is that consistent, accurate declarations correlate with fewer…
-
Counter-ion form: the field almost nobody reports — one year on Replied, post #10 · Analytics › COA interpretation · 19 Feb 2025 · 1 like Answering the question post #8 raises rather than the one it answers. Two people in this thread mean different things by Counter-ion form and are disagreeing about the…
-
Review: a draft on reconstitution arithmetic, with objections Replied, post #20 · Documentation › Doc review · 13 Feb 2025 · 0 likes Reviewing your own nomination is fine and is not sufficient. Somebody else has to read it for the process to mean anything. I am confident about the direction and much…
-
Canadian access and provincial variation Replied, post #81 · Regional › North America · 11 Feb 2025 · 1 like Speaking only to canadian access and provincial variation as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the…
-
Canadian access and provincial variation Replied, post #62 · Regional › North America · 6 Feb 2025 · 11 likes My position on canadian access and provincial variation is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.
-
Coming back to: Why the cheapest option is often not the cheapest Replied, post #9 · Access › Pricing · 29 Jan 2025 · 2 likes A cheaper option that arrives slowly has a cost in the form of running out, and people rarely price that.
-
Research-use-only status: what it means legally and practically — a second dataset Replied, post #73 · Compounds › Other compounds · 26 Jan 2025 · 0 likes Post #70 is the version of this I will quote in future. One addition. Checked the Research-use-only status claim against the primary source this morning. It survives,…
-
[2026 update] New subcategory: rationale and scope Replied, post #159 · Meta › Announcements · 18 Jan 2025 · 7 likes Coming back to post #155, because the follow-up matters more than the original answer. Where the New subcategory discussion usually stalls is that nobody wants to say…
-
Recovery when intake is low: what to cut first Replied, post #6 · Nutrition & Training › Resistance training · 9 Jan 2025 · 0 likes Where somebody is losing strength rapidly, the first questions are intake, sleep and total training volume, in that order.
-
Fixed versus detachable needles: the trade-offs Replied, post #96 · Devices › Syringes & needles · 7 Jan 2025 · 0 likes Nothing to add on the substance. Thank you for taking the question at face value.
-
What a seizure notice actually says Replied, post #21 · Sourcing › Logistics · 3 Jan 2025 · 8 likes Declaring contents accurately: declaring accurately reduces intervention risk. A declaration of "peptide research chemical, 5 grams" is better than "vitamin" or "other"…
-
Oral semaglutide bioavailability and its variability between people — a second dataset Replied, post #88 · Compounds › Oral incretins · 27 Dec 2024 · 0 likes Picking up post #85: that is the part I would want checked first. Oral semaglutide's bioavailability is low and variable, which is why the dose numbers are an order of…
-
Dose numbers for oral formulations are not comparable to injectable ones — a second… Replied, post #2 · Compounds › Oral incretins · 27 Dec 2024 · 2 likes Narrowing the opening post, because the general version has more than one answer. PIONEER 6 is the cardiovascular outcome trial for oral semaglutide and it enrolled a…
-
Reporting a good result: why nobody bothers and why they should — one year on Replied, post #13 · Sourcing › Vendor reports · 13 Dec 2024 · 10 likes Disputed records: when a result disagreed and was not explained, the record says disputed and stays that way. We do not remove inconvenient history; we document it. I…
-
Two sessions a week versus four: what the evidence supports Replied, post #29 · Nutrition & Training › Resistance training · 10 Dec 2024 · 16 likes Frequency: three sessions per week of full-body training is easier to maintain than higher frequencies on an energy deficit. Consistency beats intensity when recovery…
-
[2026 update] How to read a forest plot, properly, from scratch Replied, post #25 · Evidence › Trials · 9 Dec 2024 · 0 likes Post #22 is the version of this I will quote in future. One addition. A treatment-policy estimand asks what happens to people assigned to a strategy, including those…
-
Oxidation and deamidation mass shifts, tabulated Replied, post #14 · Analytics › Mass spectrometry · 2 Dec 2024 · 2 likes Building on post #13 rather than restating it. Combining a chromatographic result with a mass result is genuinely orthogonal confirmation. Either alone leaves a…
-
TB-500 and thymosin beta-4: the fragment versus the protein — does this still hold? Replied, post #9 · Compounds › Repair & healing peptides · 28 Nov 2024 · 0 likes Reading this TB-500 and thymosin beta-4 thread as someone who came in with a fixed view: the third and seventh replies moved me and the confident ones did not.
-
Why I ask for the gradient before I discuss the number Replied, post #38 · Analytics › HPLC & UHPLC · 23 Nov 2024 · 5 likes I had written a reply contradicting post #36 and deleted it. Here is what survived. Mobile-phase preparation is a genuine source of between-laboratory variation. Acid…
-
Reading a preclinical wound-healing model and its relevance to a human tendon Replied, post #95 · Compounds › Repair & healing peptides · 19 Nov 2024 · 21 likes Dose-response is unstudied in humans for essentially everything in this family, which means the confident numbers in circulation came from somewhere other than a trial.…
-
Hypertension improvement and when medication needs revisiting — a second dataset Replied, post #134 · Clinical › Comorbidities · 30 Oct 2024 · 0 likes Post #132 describes the usual case. This is about the unusual one. Two sentences on Hypertension improvement and then I will stop, because the rest is speculation and…
-
Second pass at: Hoarding and why it makes a shortage worse Started this topic · Access › Shortages · 8 Oct 2024 · 1 like Second pass at: Hoarding and why it makes a shortage worse Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access…
-
Revisiting: How to bring a laboratory report to an appointment usefully Replied, post #43 · Clinical › Bloodwork · 20 Sep 2024 · 1 like The most useful thing this subcategory does is help people tell an interesting result from an uninteresting one before booking an appointment about it.
-
Progressive overload when the scale is falling — one year on Replied, post #68 · Nutrition & Training › Resistance training · 18 Sep 2024 · 11 likes Post #65 is the version of this I will quote in future. One addition. Nothing here is medical advice and anybody with a relevant condition should have a programme…
-
Second pass at: Sodium, potassium and magnesium when intake drops Replied, post #86 · Nutrition & Training › Hydration & electrolytes · 10 Sep 2024 · 11 likes Post #83 answers the question as asked. The question underneath it is different. If someone has run Sodium properly I would rather read that than my own reconstruction…
-
Correlation in a self-tracked dataset: what it can support Replied, post #34 · Research Methods › Statistics · 21 Aug 2024 · 1 like Practical experience of correlation, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it…
-
Coming back to: Purity assay versus content assay: two different numbers Replied, post #44 · Analytics › COA interpretation · 11 Aug 2024 · 5 likes Counter-ion form belongs on the document and almost never is. Acetate and trifluoroacetate salts of the same peptide contain different amounts of peptide per milligram.…
-
Guidelines revision: what changed and why Replied, post #102 · Meta › Announcements · 28 Jul 2024 · 7 likes Worth saying publicly: stepping back cleanly and handing over is a service. Documents with an absent maintainer go wrong quietly, which is the worst way for them to go…
-
Merging two pages that cover the same ground — the long version Replied, post #2 · Documentation › Wiki requests · 22 Jul 2024 · 1 like Everything in the opening post holds. The case it does not cover is the one I have. Say what would make the page wrong. A page whose failure conditions are stated is…
-
How this community labels and discusses unrefereed work Replied, post #52 · Evidence › Preprints · 1 Jul 2024 · 5 likes A preprint with the data and code attached is frequently more checkable than a published paper without them. Reviewed and reproducible are different properties.
-
Blind submission and why it changes minds Replied, post #5 · Sourcing › Independent verification · 26 Jun 2024 · 3 likes A record with four results over sixteen months is a thin record rather than a bad one, and the honest description says which. A modest claim, modestly supported.
-
How this community labels and discusses unrefereed work Replied, post #16 · Evidence › Preprints · 13 Jun 2024 · 0 likes Answering the community labels question as asked, then the question I think is meant. As asked: yes, with the qualification below. As meant: it depends on how the first…